Welcome to our dedicated page for AUTOLUS THERAPEUTICS PLC SEC filings (Ticker: AUTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Autolus Therapeutics plc (Nasdaq: AUTL) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a commercial-stage biopharmaceutical issuer. Autolus is incorporated in England and Wales, and its American Depositary Shares trade on The Nasdaq Global Select Market. As a foreign private issuer, Autolus files reports and current disclosures with the U.S. Securities and Exchange Commission, including Forms 20-F and 6-K, as well as current reports on Form 8-K related to material events.
In its filings, Autolus provides information on its business of developing, manufacturing and delivering next-generation programmed T cell therapies for cancer and autoimmune disease. Investors can use these documents to follow the commercial launch and performance of AUCATZYL® (obecabtagene autoleucel; obe-cel), a CD19-directed genetically modified autologous T cell immunotherapy indicated for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Filings often reference net product revenue, cost of sales, research and development expenses, and selling, general and administrative expenses, as well as cash, cash equivalents and marketable securities.
Current reports on Form 8-K for Autolus have included quarterly financial results, corporate updates, and governance changes such as the appointment of a principal accounting officer. These documents can also incorporate press releases that discuss clinical trial progress in programs like CATULUS, CARLYSLE, LUMINA, BOBCAT and ALARIC, and provide context on how Autolus is advancing its pipeline across hematological malignancies, solid tumors and autoimmune diseases.
On Stock Titan, SEC filings for AUTL are updated in near real time from EDGAR. Integrated AI-powered summaries help explain the key points in lengthy filings, including annual reports, interim financial updates and material event disclosures. Users can quickly scan for information on Autolus’ T cell programming technologies, AUCATZYL commercialization, manufacturing initiatives and capital position without reading every line of the underlying documents.
MAK Capital Fund LP, MAK Capital One L.L.C., and Michael A. Kaufman have disclosed a passive ownership stake in Autolus Therapeutics plc (NASDAQ: AUTL) via Schedule 13G. The group reports beneficial ownership of 15,408,638 American Depositary Shares (ADS), equal to 5.8 % of the company’s 266,141,411 ordinary shares/ADS outstanding as of 7 May 2025. All voting and dispositive authority over the shares is held on a shared basis; none is held solely by any individual entity. MAK Capital Fund is organized in Bermuda, while MAK Capital One L.L.C. and Mr. Kaufman are U.S.-based (Delaware). The filing is made under Rule 13d-1(c), indicating the stake is passive rather than activist; the certification expressly states the securities were not acquired to influence control of the issuer. The event triggering the filing occurred on 17 June 2025, and signatures were executed on 25 June 2025.
The disclosure is material because it crosses the 5 % threshold that requires public reporting, signaling meaningful institutional interest. However, the absence of sole voting power and the passive filing status reduce the likelihood of immediate governance changes. Investors may view the stake as a constructive vote of confidence in Autolus’ long-term prospects without signaling imminent strategic pressure.